Guggenheim downgraded HilleVax to Neutral from Buy and removed the firm’s price target following the “extremely disappointing results” from the event-driven Phase 2 pediatric study. With just a 5% VE separation and the pediatric opportunity being core to the firm’s thesis, the firm expects shares to trade at or below cash for the foreseeable future, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLVX: